Pharmacological behavioural preclinical studies proven that SB266970 has an antipsychotic action with rapid-acting antidepressant effects, as opposed to standard monoaminergic antidepressants, and it augments the actions of standard monoaminergic antidepressants [193]

Pharmacological behavioural preclinical studies proven that SB266970 has an antipsychotic action with rapid-acting antidepressant effects, as opposed to standard monoaminergic […]